Clinical trials: Neovascular Age Related Macular Degeneration
Neovascular Age-Related Macular Degeneration
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
- Trial name
- NCT06198413
- Testing
- LX102 subretinal injection
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
Age-related Macular Degeneration, Choroidal Neovascularization
Imaging of the Angiofibrotic Switch in Neovascular AMD
The content of this research project is to identify the angiofibrotic switch, the transition from angiogenesis to fibrosis, in neovascular age-related macular degeneration (nAMD) longitudinally.
- Trial name
- NCT03838679
- Testing
- Best-corrected Visual acuity testing (BCVA), Optical coherence tomography (OCT), Color fundus photography (CFP)
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Medical University of Vienna
Dystrophy, Retinal
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.
- Trial name
- NCT04690062
- Testing
- Brolucizumab-Dbll
- Where
- United Arab Emirates
- Volunteers
- 20 people
- Sponsor
- Benha University
Neovascular Maculopathy, Age Related Macular Degeneration
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 or A*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in patients with Neovascular Maculopathy…
- Trial name
- NCT00791570
- Testing
- VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Osaka University
Macular Degeneration
High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration
This study will use an eye imaging test called high speed indocyanine green angiography (HS-ICG), which examines leaky vessels in the eye, to try to find out why individuals respond differently to ranibizumab (Lucentis) treatment…
- Trial name
- NCT00656903
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
- Trial name
- NCT07550504
- Testing
- SB11 PFS
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Macula; Degeneration, Retina
Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)
This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD.
- Trial name
- NCT03197493
- Testing
- carbidopa-levodopa 25-100 mg
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Macular Degeneration
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
- Trial name
- XPLORE (NCT03805100)
- Testing
- Ranibizumab
- Where
- 102 sites in United States, Bulgaria and 13 more
- Volunteers
- 582 people
- Sponsor
- Xbrane Biopharma AB
Exudative Macular Degeneration
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.
- Trial name
- NCT01617148
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rishi Singh
Age-related Macular Degeneration
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular…
- Trial name
- NCT00782093
- Testing
- volociximab
- Volunteers
- 63 people
- Sponsor
- Ophthotech Corporation
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
- Trial name
- NCT05972473
- Testing
- Aflibercept Ophthalmic, IBI302
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Age-Related Macular Degeneration
Beovu Experience UZ Leuven
Reporting early real-world clinical data of consecutive patients on the use of Beovu® (brolucizumab) intravitreal injections in patients with neovascular age-related macular degeneration.
- Trial name
- BEL (NCT05220085)
- Testing
- Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Acute Macular Degeneration
The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity
Currently the best treatment for "wet" macular degeneration involves regular injections of Ranibizumab (Lucentis). In the initial clinical trials, the drug was injected into the eye every month.
- Trial name
- NCT02304068
- Testing
- Home monitoring, Hospital assessment
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Age-Related Macular Degeneration
TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to…
- Trial name
- VERTACL (NCT00464347)
- Testing
- Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
This is a prospective, multicenter, single arm study. The study group will be compose of NVAMD patients who had partial or complete failure responding to initial bevacizumab or ranibizumab treatment of 3-6 monthly intravitreal…
- Trial name
- NCT01918878
- Testing
- Aflibercept (EYLEA)
- Where
- Israel
- Volunteers
- 48 people
- Sponsor
- Hadassah Medical Organization
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
A study investigating the ability of OCTA imaging technology to identify and analyze untreated type 1, 2, and 3 neovascular membrane lesions in treatment naive patients with exudative macular degeneration, as well as…
- Trial name
- IAI-OCTA (NCT03022292)
- Testing
- Aflibercept Ophthalmic, optovue angiovue
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Neovascular Age Related Macular Degeneration
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations…
- Trial name
- NCT03930641
- Testing
- RTH258
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration, Pigment Epithelial Detachment
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis).
- Conditions
- Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
- Trial name
- DETAIL (NCT00590694)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Pacific Eye Associates